

### Daftar Pustaka

Addeo, P., Jedidi, I., Locicero, A., Faitot, F., Oncioiu, C., Onea, A., & Bachellier, P. (2019). Prognostic Impact of Tumor Multinodularity in Intrahepatic Cholangiocarcinoma. *Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract*, 23(9), 1801–1809. <https://doi.org/10.1007/s11605-018-4052-y>

Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of kolangiokarsinoma: 1990-2009. *World J Gastroenterol* 2009; 15: 4240-4262 [PMID: 19750567 DOI: 10.3748/wjg.15.4240]

Ali, C. W., Kaye, T. F., Adamson, D. J., Tait, I. S., Polignano, F. M., & Highley, M. S. (2007). CA 19-9 and survival in advanced and *unresectable* pancreatic adenocarcinoma and cholangiocarcinoma. *Journal of gastrointestinal cancer*, 38(2-4), 108-114.

Alvaro D, Bragazzi MC, Benedetti A, et al. Kolangiokarsinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the 'kolangiokarsinoma' committee of the Italian Association for the Study of Liver disease. *Dig Liver Dis* 2011;43:60–5.

Amin, M. B. et al. *AJCC Cancer Staging Manual* (Springer, 2017).

Ariff B, Lloyd CR, Khan S, et al. Imaging of liver cancers. *World J Gastroenterol* 2009;15:1289e300.

Bagante F., Spolverato G., Merath K., Weiss M., Alexandrescu S., Marques H.P., Aldrighetti L., Maithel S.K., Pulitano C., Bauer T.W. Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. *Surgery*. 2019;166:983–990. doi: 10.1016/j.surg.2019.06.005.

Banales, J. M. et al. Expert consensus document: kolangiokarsinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Kolangiokarsinoma (ENS-CCA). *Nat. Rev. Gastroenterol. Hepatol.* 13, 261–280 (2016).

Banales, J.M., Marin, J.J.G., Lamarca, A. et al. Kolangiokarsinoma 2020: the next horizon in mechanisms and management. *Nat Rev Gastroenterol Hepatol* 17, 557–588 (2020). <https://doi.org/10.1038/s41575-020-0310-z>

Bergquist A, von Seth E: Epidemiology of kolangiokarsinoma. *Best Pract Res Clin Gastroenterol* 2015;29: 221–232.

Bi, C., Wang, L. M., An, S. L., Huang, J., Feng, R. M., Wu, F., Rong, W. Q., & Wu, J. X. (2016). *Zhonghua zhong liu za zhi [Chinese journal of oncology]*, 38(6), 466–471. <https://doi.org/10.3760/cma.j.issn.0253-3766.2016.06.012>

Blechacz B, Gores GJ: Kolangiokarsinoma: advances in pathogenesis, diagnosis, and treatment. *Hepatology* 2008;48:308–321.

Brandi, G. et al. Asbestos: a hidden player behind the kolangiokarsinoma increase? Findings from a case- control analysis. *Cancer Causes Control* 24, 911–918 (2013).

Brivio, S., Cadamuro, M., Strazzabosco, M. & Fabris, L. Tumor reactive stroma in kolangiokarsinoma: the fuel behind cancer aggressiveness. *World J. Hepatol.* 9, 455–468 (2017).

Brown EG, Canter RJ, Bold RJ (2015) Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma. *J Surg Oncol* 111(3):293–298. doi:10.1002/jso.23812

Cai, Z., He, C., Zhao, C., & Lin, X. (2021). Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma. *Frontiers in oncology*, 11, 1115.

Cancer.Net. 2021. Bile Duct Cancer (Cholangiocarcinoma) - Statistics. [online] Available at: <<https://www.cancer.net/cancer-types/bile-duct-cancer-cholangiocarcinoma/statistics>> [Accessed 20 July 2021].

Cancer.org. 2021. Bile Duct Cancer Survival Rates | Cholangiocarcinoma Survival Rates. [online] Available at: <<https://www.cancer.org/cancer/bile-duct-cancer/detection-diagnosis-staging/survival-by-stage.html>> [Accessed 19 July 2021].

Chang, J. I., Lee, K., Kim, D., Yang, J. I., Park, J. K., Choi, K., Kang, S. H., Lee, K. H., Lee, K. T., Lee, J. K., Park, S. M., & Park, J. K. (2021). Clinical Characteristics of *Clonorchis sinensis*-Associated Cholangiocarcinoma: A Large-Scale, Single-Center Study. *Frontiers in medicine*, 8, 675207. <https://doi.org/10.3389/fmed.2021.675207>

Chen G, Yu H, Wang Y, et al. A novel nomogram for the prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis complicated by imagiologically diagnosed mass. *Cancer Manag Res.* 2018;10:847-856. Published 2018 Apr 23. doi:10.2147/CMAR.S157506

Cho, Y., Kim, T. H., & Seong, J. (2017). Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Verbesserte onkologische Ergebnisse mit Chemoradiotherapie gefolgt von einer Operation beim nichtresezierbaren intrahepatischen Cholangiokarzinom. *Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]*, 193(8), 620–629. <https://doi.org/10.1007/s00066-017-1128-7>

Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. *J Hepatol* 2009;50:158e64.

Clements, O., Eliahoo, J., Kim, J. U., Taylor- Robinson, S. D. & Khan, S. A. Risk factors for intrahepatic and extrahepatic kolangiokarsinoma: a systematic review and meta-analysis. *J. Hepatol.* 72, 95–103 (2020).

Cristina Mosconi, Matteo Renzulli, Emanuela, et al. Unresectable Perihilar Kolangiokarsinoma: Multimodal Palliative Treatment. *Anticancer Research.* June 2013, 33.

Coelho, Rosa, et al. "CA 19-9 as a marker of survival and a predictor of metastization in cholangiocarcinoma." *GE-Portuguese Journal of Gastroenterology* 24.3 (2017): 114-121.

Das, V., Kalita, J. & Pal, M. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. *Biomed. Pharmacother.* 87, 8–19 (2017).

DeOliveira, M. L. et al. Kolangiokarsinoma: thirty-one- year experience with 564 patients at a single institution. *Ann. Surg.* 245, 755–762 (2007).

Doherty, B., Nambudiri, V. and Palmer, W., 2017. Update on the Diagnosis and Treatment of Kolangiokarsinoma. *Current Gastroenterology Reports*, 19(1).

Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Kolangiokarsinomas can originate from hepatocytes in mice. *J Clin Invest* 2012;122:2911–2915.

Fang T, Wang H, Wang Y, Lin X, Cui Y, Wang Z. Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma. *Dis Markers*. 2019;2019:6016931. Published 2019 Feb 4. doi:10.1155/2019/6016931

Farioli, A. et al. Occupational exposure to asbestos and risk of kolangiokarsinoma: a population- based case- control study in four Nordic countries. *Occup. Env. Med.* 75, 191–198 (2018).

Forner, A. et al. Clinical presentation, diagnosis and staging of kolangiokarsinoma. *Liver Int.* 39 (Suppl. 1), 98–107 (2019).

Gores GJ. Early detection and treatment of kolangiokarsinoma. *Liver Transpl* 2000;6(6 Suppl 2):S30e4.

Guilbaud, T., Girard, E., Lemoine, C., Schlienger, G., Alao, O., Risse, O., Berdah, S., Chirica, M., Moutardier, V., & Birnbaum, D. J. (2021). Intra-pancreatic distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: a common short and long-term prognosis?. *Updates in surgery*, 73(2), 439–450. <https://doi.org/10.1007/s13304-021-00981-0>

Gupta, A., Agrawal, S., Gupta, S., Goyal, B., Siddeek, R., Rajput, D., Chauhan, U., Kishore, S., Gupta, M. and Kant, R., 2020. Role of carbohydrate antigen 19-9, carcinoembryonic antigen, and carbohydrate antigen 125 as the predictors of resectability and survival in the patients of Carcinoma Gall Bladder. *Journal of Carcinogenesis*, 19(1), p.4.

Hu, Hai-Jie & Mao, Hui & Tan, Yong-Qiong & Shrestha, Anuj & Ma, Wen-Jie & Yang, Qin & Wang, Jun-Ke & Cheng, Nan-Sheng & Li, Fu-Yu. (2016). Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar kolangiokarsinoma. *SpringerPlus*. 5. 10.1186/s40064-016-2181-x.

Ishikawa, Y., Wada, I. & Fukumoto, M. Alpha- particle carcinogenesis in Thorotrast patients: epidemiology, dosimetry, pathology, and molecular analysis. *J. Env. Pathol. Toxicol. Oncol.* 20, 311–315 (2001).

Jhaveri, K. S. & Hosseini- Nik, H. MRI of kolangiokarsinoma. *J. Magn. Reson. Imaging* 42, 1165–1179 (2015).

Jing, W. et al. Diabetes mellitus and increased risk of kolangiokarsinoma: a meta-analysis. *Eur. J. Cancer Prev.* 21, 24–31 (2012).

Joo, I., Lee, J. M. & Yoon, J. H. Imaging diagnosis of intrahepatic and perihilar kolangiokarsinoma: recent advances and challenges. *Radiology* 288, 7–13 (2018).

Jun, S. Y., An, S., Sung, Y. N., Park, Y., Lee, J. H., Hwang, D. W., & Hong, S. M. (2020). Clinicopathologic and Prognostic Significance of Gallbladder and Cystic Duct Invasion in Distal Bile Duct Carcinoma. *Archives of pathology & laboratory medicine*, 144(6), 755–763. <https://doi.org/10.5858/arpa.2019-0218-OA>

Juntermanns, B., Radunz, S., Heuer, M., Hertel, S., Reis, H., Neuhaus, J. P., Vernadakis, S., Trarbach, T., Paul, A., & Kaiser, G. M. (2010). Tumor markers as a diagnostic key for hilar cholangiocarcinoma. *European journal of medical research*, 15(8), 357–361. <https://doi.org/10.1186/2047-783x-15-8-357>

Kato, Y., Takahashi, S., Gotohda, N. & Konishi, M. Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer. *J. Gastrointest. Surg.* 20, 1435–43 (2016).

Khan SA, Davidson BR, Goldin R, et al. UK guidelines for the diagnosis and treatment of kolangiokarsinoma. *Gut* 2002;51(Suppl 6):VIIe9.

Khan SA, Taylor-Robinson SD, Davidson BR, et al. Kolangiokarsinoma: seminar. *Lancet* 2005;366:1303e14.

Khan, S. A., Tavorari, S. & Brandi, G. Kolangiokarsinoma: epidemiology and risk factors. *Liver Int.* 39 (Suppl. 1), 19–31 (2019).

Kim JY, Kim MH, Lee TY, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable kolangiokarsinoma: a prospective study compared with conventional imaging. *Am J Gastroenterol* 2008;103:1145e51.

Kosin Wirasorn, Thundon Ngamprasertchai, Jarin Chindaprasirt, Aumkhae S Prognostic factors in resectable kolangiokarsinoma patients: Carcinoembryonic antigen, lymph node, surgical margin and chemotherapy

Kumagai, S. et al. Relationship between cumulative exposure to 1,2-dichloropropane and incidence risk of kolangiokarsinoma among offset printing workers. *Occup. Env. Med.* 73, 545–552 (2016).

Lee, A. and Chun, Y., 2018. Intrahepatic kolangiokarsinoma: the AJCC/UICC 8th edition updates. *Chinese Clinical Oncology*, 7(5), pp.52-52.

Lee, B. S., Lee, S. H., Son, J. H., Jang, D. K., Chung, K. H., Paik, W. H., Ryu, J. K., & Kim, Y. T. (2016). Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. *Journal of gastroenterology and hepatology*, 31(2), 493–500. <https://doi.org/10.1111/jgh.13059>

Li, F. H., Chen, X. Q., Luo, H. Y., Li, Y. H., Wang, F., Qiu, M. Z., Teng, K. Y., Li, Z. H., & Xu, R. H. (2009). *Ai zheng = Aizheng = Chinese journal of cancer*, 28(5), 528–532.

Li, H., Chen, L., Zhu, G. Y., Yao, X., Dong, R., & Guo, J. H. (2021). Interventional Treatment for Cholangiocarcinoma. *Frontiers in oncology*, 11.

Lieser, M. J., Barry, M. K., Rowland, C., Ilstrup, D. M., & Nagorney, D. M. (1998). Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. *Journal of hepato-biliary-pancreatic surgery*, 5(1), 41-47.

Lin, M.-S., Huang, J.-X. & Yu, H. Elevated Serum Level of Carbohydrate antigen 19-9 in Benign Biliary Stricture Diseases can Reduce its Value as a Tumor Marker. *Int. J.Clin. Exp. Med.* 7, 744–50 (2014).

Li Z., Yuan L., Zhang C., Sun J., Wang Z., Wang Y., Hao X., Gao F., Jiang X. A Novel Prognostic Scoring System of Intrahepatic Cholangiocarcinoma With Machine Learning Basing on Real-World Data. *Front. Oncol.* 2021;10:3146.

Loosen, Sven H., et al. "CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma." *Scientific reports* 7.1 (2017): 1-10.

Lozano, E. et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. *Mol. Cancer Res.* 12, 91–100 (2014).

Malone, C. D., Gibby, W., Tsai, R., Kim, S. K., Lancia, S., Akinwande, O., & Ramaswamy, R. S. (2020). Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma. *Journal of vascular and interventional radiology : JVIR*, 31(5), 701–709. <https://doi.org/10.1016/j.jvir.2019.09.028>

Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. *Am J Surg* 2009; 198: 333-339

Morine Y, Shimada M, Takamatsu H, et al. Clinical features of pancreaticobiliary maljunction: update analysis of 2nd Japan-nationwide survey. *J Hepatobiliary Pancreat Sci* 2013;20:472–80.

Moro, A., Mehta, R., Sahara, K. et al. The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma. *Ann Surg Oncol* 27, 2888–2901 (2020). <https://doi.org/10.1245/s10434-020-08350-8>

Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. *Hepatobiliary Pancreat Dis Int* 2009; 8: 620-626

MOSCONI, C., RENZULLI, M., GIAMPALMA, E., GALUPPI, A., BALACCHI, C., BRANDI, et al. 2013. Unresectable Perihilar Cholangiocarcinoma: Multimodal Palliative Treatment. *ANTICANCER RESEARCH*, (33), p.2747.

Nakeeb A, Lipsett PA, Lillemoe KD, et al (1996). Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. *Am J Surg*, 171, 147-53. Nanashima A, Sumida Y, Abo T, et al (2007).

Ni, X. G., Bai, X. F., Mao, Y. L., Shao, Y. F., Wu, J. X., Shan, Y., Wang, C. F., Wang, J., Tian, Y. T., Liu, Q., Xu, D. K., & Zhao, P. (2005). The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*, 31(2), 164–169. <https://doi.org/10.1016/j.ejso.2004.09.007>

Nicholson,B.D.et al. in Cochrane Database of Systematic Reviews (ed. Nicholson, B. D.) CD011134, <https://doi.org/10.1002/14651858.CD011134.pub2> (John Wiley & Sons,Ltd, 2015).

Nonomura, A. et al. Immunohistochemical localization of ras p21 and carcino embryonic antigens (CEA) in kolangiokarsinoma Liver 7, 142–8 (1987).

Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia. 2003;58(5):667-672.

Pak, K., Kim, S. J., Kim, I. J., Kim, D. U., Kim, K., Kim, H., & Kim, S. J. (2014). Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma. *Nuklearmedizin. Nuclear medicine*, 53(2), 26–31. <https://doi.org/10.3413/Nukmed-0566-13-03>

Petrick, J. L. et al. Risk factors for intrahepatic and extrahepatic kolangiokarsinoma in the United States: a population- based study in SEER- Medicare. PLoS One 12, e0186643 (2017).

Plentz RR, Malek NP: Clinical presentation, risk factors and staging systems of kolangiokarsinoma. Best Pract Res Clin Gastroenterol 2015;29:245–252.

Qiang, Z., Zhang, W., Jin, S., Dai, K., He, Y., Tao, L., & Yu, H. (2021). Carcinoembryonic antigen,  $\alpha$ -fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: A retrospective cohort study. *Annals of hepatology*, 20, 100242. <https://doi.org/10.1016/j.aohep.2020.07.010>

Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. *World J Gastroenterol*. 2004;10(3):427-432. doi:10.3748/wjg.v10.i3.427

Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. *Gastroenterology* 1995; 108: 865-869

Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Kolangiokarsinoma - evolving concepts and therapeutic strategies. *Nat. Rev. Clin. Oncol*. 15, 95–111 (2018).

Ruys, A., van Haelst, S., Busch, O., Rauws, E., Gouma, D. and van Gulik, T., 2012. Long-term Survival in Hilar Kolangiokarsinoma also Possible in Unresectable Patients. *World Journal of Surgery*, 36(9), pp.2179-2186.

Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. *Cancer*. 2016;122(1):61–70. doi:<https://doi.org/10.1002/cncr.29686>

Sasaki K, Margonis GA, Andreatos N, Bagante F, Weiss M, Barbon C et al. Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. *J Am Coll Surg*. 2018;226(4):393–403. doi: <https://doi.org/10.1016/j.jamcollsurg.2017.12.011>



Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. *Biometrics* 1983;39:499-503.

Sheen-Chen, et al (2007). Patient outcome and prognostic factors in intrahepatic cholangiocarcinoma after hepatectomy. *Hepatogastroenterology*, 54, 2337-42.

Shen, Z. T., Zhou, H., Li, A. M., Li, B., Shen, J. S., & Zhu, X. X. (2017). Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma. *Oncotarget*, 8(55), 93541–93550.  
<https://doi.org/10.18632/oncotarget.19972>

Shin, H. R. et al. Epidemiology of kolangiokarsinoma:an update focusing on risk factors. *Cancer Sci.* 101579–585 (2010).

Shimizu, S., Okumura, T., Oshiro, Y., Fukumitsu, N., Fukuda, K., Ishige, K., *et al.* 2019. Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy. *Radiation Oncology*, 14(1).

Sia, D. et al. Integrative molecular analysis of intrahepatic kolangiokarsinoma reveals 2 classes that have different outcomes. *Gastroenterology* 144, 829–840 (2013).

Singal, A. G., et al. "The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre." *Alimentary pharmacology & therapeutics* 31.6 (2010): 625-633.

S. R. Z. Abdel-Misih, I. Hatzaras, C. Schmidt et al., "Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease," *Annals of Surgical Oncology*, vol. 18, no. 4, pp. 1116–1121, 2011.

Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H, Orntoft TF. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. *Clin Chem* 1999; 45: 54-61

Wang, Y., Li, J., Xia, Y., Gong, R., Wang, K., Yan, Z., ... & Shen, F. (2013). Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. *J Clin Oncol*, 31(9), 1188-1195.

Wang Y-Y, Zhong J-H, Lu Z, Qin H-G, Li L-Q (2015) Does the elevation of serum carbohydrate antigen 19-9 level predict poor overall survival in patients with hepatocellular carcinoma? *Tumor Biol.* doi:10.1007/s13277-015-4326-x

Wang, Yizhou, et al. "Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy." *J Clin Oncol* 31.9 (2013): 1188-1195.

Wirasorn, K., Ngamprasertchai, T., Chindaprasert, J., Sookprasert, A., Khantikaew, N., Pakkhem, A., & Ungareerevittaya, P. (2013). Prognostic factors in resectable cholangiocarcinoma patients: Carcinoembryonic antigen, lymph node, surgical margin and chemotherapy. *World journal of gastrointestinal oncology*, 5(4), 81–87.  
<https://doi.org/10.4251/wjgo.v5.i4.81>

Wongjarupong, N. et al. Non- alcoholic fatty liver disease as a risk factor for kolangiokarsinoma: a systematic review and meta- analysis. *BMC Gastroenterol.* 17, 149 (2017).

Yamamoto Y, Sugiura T, Okamura Y, et al. The Evaluation of the Eighth Edition of the AJCC/UICC Staging System for Intrahepatic Cholangiocarcinoma: a Proposal of a Modified New Staging System. *J Gastrointest Surg.* 2020;24(4):786-795. doi:10.1007/s11605-019-04185-1

Yao, K. J., Jabbour, S., Parekh, N., Lin, Y. & Moss, R. A. Increasing mortality in the United States from kolangiokarsinoma: an analysis of the National Center for Health Statistics Database. *BMC Gastroenterol.* 16, 117 (2016).

Yeh, C. N., Jan, Y. Y., & Chen, M. F. (2006). Hepatectomy for peripheral cholangiocarcinoma in elderly patients. *Annals of surgical oncology*, 13(12), 1553–1559. <https://doi.org/10.1245/s10434-006-9085-x>

Yoo, T., Park, S. J., Han, S. S., Kim, S. H., Lee, S. D., Kim, Y. K., ... & Hong, E. K. (2015). Postoperative CA19-9 change is a useful predictor of intrahepatic cholangiocarcinoma survival following liver resection. *Disease markers*, 2015.

Zhang J-X, Song W, Chen Z-H, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. *The Lancet Oncology.* 2013/12/01/2013;14(13):1295–306.

Zhang, L., Cai, J. Q., Bi, X. Y., Zhao, J. J., Xing, G. S., Yan, T., Fu, Y. X., & Zhao, P. (2009). *Zhonghua zhong liu za zhi [Chinese journal of oncology]*, 31(11), 845–848.

Zhang, Y. et al. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. *Int.J.Clin.Exp.Med.* 8, 11683–91 (2015).

Zhang, Y., Wu, Z., Wang, X., Li, C., Chang, J., Jiang, W., Wang, H., Wang, Y., & Li, X. (2020). Development and external validation of a nomogram for predicting the effect of tumor size on survival of patients with perihilar cholangiocarcinoma. *BMC cancer*, 20(1), 1044. <https://doi.org/10.1186/s12885-020-07501-0>

Zhao, B., Cheng, Q., Cao, H., Zhou, X., Li, T., Dong, L., & Wang, W. (2021). Dynamic change of serum CA19–9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas. *BMC cancer*, 21(1), 1–8.

Zografos GN, Farfaras A, Zagouri F, Chrysikos D, Karaliotas K. Kolangiokarsinoma: principles and current trends. *Hepatobiliary Pancreat Dis Int* 2011; 10: 10-20 [PMID: 21269929]